步長製藥(603858.SH):兩家子公司藥品生產許可證變更
格隆匯1月8日丨步長製藥(603858.SH)公佈,公司近日獲悉全資子公司通化谷紅製藥有限公司(以下簡稱“通化谷紅”)、控股子公司通化天實製藥有限公司(以下簡稱“通化天實”)獲得吉林省藥品監督管理局許可,同意通化谷紅《藥品生產許可證》生產地址和生產範圍由“吉林省梅河口市北環東路1666號:小容量注射劑***”變更為“吉林省梅河口市北環東路1666號:小容量注射劑,中藥前處理及提取***吉林省梅河口市建國路5099號:中藥前處理及提取,小容量注射劑***”,分類碼由“HbZb”變更為“Ahz”,質量負責人由“杜鵑”變更為“楊昊”。同意通化天實《藥品生產許可證》生產範圍增加“中藥前處理及提取***”,分類碼由“HbZb”變更為“Ahz”,其他內容不變。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.